The lack of inhibition of TNF-α shedding in vivo might explain the relatively modest antitumour effect of the antibody, because TNF-α was thought to be a key driver of tumour growth in this model, based on the shRNA work of Kulbe, etal[37], but the infliximab data confounds this hypothesis (see below). Here, TNF is linked to neoplasm.